These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 39607603)

  • 1. A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM.
    Ishida T; Kuroda Y; Matsue K; Komeno T; Ishiguro T; Ishikawa J; Ito T; Kosugi H; Sunami K; Nishikawa K; Shibayama K; Aida K; Yamazaki H; Inagaki M; Kobayashi H; Iida S
    Int J Hematol; 2024 Nov; ():. PubMed ID: 39607603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of Drug-Drug Interaction Potential of Talquetamab, a T-Cell-Redirecting GPRC5D × CD3 Bispecific Antibody, as a Result of Cytokine Release Syndrome in Patients with Relapsed/Refractory Multiple Myeloma in MonumenTAL-1, Using a Physiologically Based Pharmacokinetic Model.
    Willemin ME; Gong J; Hilder BW; Masterson T; Tolbert J; Renaud T; Heuck C; Kane C; De Zwart L; Girgis S; Ma X; Ouellet D
    Target Oncol; 2024 Nov; 19(6):965-979. PubMed ID: 39285155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.
    Hamilton EP; Falchook GS; Wang JS; Fu S; Oza AM; Imedio ER; Kumar S; Ottesen L; Mugundu GM; de Bruin EC; O'Connor MJ; Jones SF; Spigel DR; Li BT
    Target Oncol; 2024 Nov; 19(6):879-892. PubMed ID: 39487373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 first-in-human study of MEDI2228, a BCMA-targeted ADC, in patients with relapsed refractory multiple myeloma.
    Dimopoulos MA; Migkou M; Bhutani M; Ailawadhi S; Kalff A; Walcott FL; Pore N; Brown M; Wang F; Cheng LI; Kagiampakis I; Williams M; Kinneer K; Wu Y; Jiang Y; Kubiak RJ; Zonder JA; Larsen J; Sirdesai S; Yee AJ; Kumar S
    Leuk Lymphoma; 2024 Dec; 65(12):1789-1800. PubMed ID: 39404476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatments for intractable constipation in childhood.
    Gordon M; Grafton-Clarke C; Rajindrajith S; Benninga MA; Sinopoulou V; Akobeng AK
    Cochrane Database Syst Rev; 2024 Jun; 6(6):CD014580. PubMed ID: 38895907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and activity of CTX130, a CD70-targeted allogeneic CRISPR-Cas9-engineered CAR T-cell therapy, in patients with relapsed or refractory T-cell malignancies (COBALT-LYM): a single-arm, open-label, phase 1, dose-escalation study.
    Iyer SP; Sica RA; Ho PJ; Prica A; Zain J; Foss FM; Hu B; Beitinjaneh A; Weng WK; Kim YH; Khodadoust MS; Huen AO; Williams LM; Ma A; Huang E; Ganpule A; Nagar SD; Sripakdeevong P; Cullingford EL; Karnik S; Dequeant ML; Patel JN; He XS; Li Z; He QA; Mendonez JH; Keegan A; Horwitz SM
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39617017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tamoxifen for adults with hepatocellular carcinoma.
    Naing C; Ni H; Aung HH
    Cochrane Database Syst Rev; 2024 Aug; 8(8):CD014869. PubMed ID: 39132750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Phase II, Open-Label Study of Lenalidomide and Dexamethasone Followed by Donor Lymphocyte Infusions in Relapsed Multiple Myeloma Following Upfront Allogeneic Stem Cell Transplant.
    LeBlanc R; Thiant S; Terra R; Ahmad I; Claveau JS; Bambace N; Bernard L; Cohen S; Delisle JS; Lachance S; Kiss T; Roy DC; Sauvageau G; Roy J
    Curr Oncol; 2024 Nov; 31(11):7258-7274. PubMed ID: 39590165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary lung tumour stereotactic body radiotherapy followed by concurrent mediastinal chemoradiotherapy and adjuvant immunotherapy for locally advanced non-small-cell lung cancer: a multicentre, single-arm, phase 2 trial.
    Heinzerling JH; Mileham KF; Robinson MM; Symanowski JT; Induru RR; Brouse GM; Corso CD; Prabhu RS; Haggstrom DE; Moeller BJ; Bobo WE; Fasola CE; Thakkar VV; Pal SE; Gregory JM; Norek SL; Begic XJ; Kesarwala AH; Burri SH; Simone CB
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39615497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial.
    Kim P; Sanchez AM; Penke TJR; Tuson HH; Kime JC; McKee RW; Slone WL; Conley NR; McMillan LJ; Prybol CJ; Garofolo PM
    Lancet Infect Dis; 2024 Dec; 24(12):1319-1332. PubMed ID: 39134085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study.
    Shah BD; Ghobadi A; Oluwole OO; Logan AC; Boissel N; Cassaday RD; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Park JH; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff P; Jeyakumar D; Feng C; Dong J; Shen T; Milletti F; Rossi JM; Vezan R; Masouleh BK; Houot R
    Lancet; 2021 Aug; 398(10299):491-502. PubMed ID: 34097852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. De-escalated neoadjuvant weekly nab-paclitaxel with trastuzumab and pertuzumab versus docetaxel, carboplatin, trastuzumab, and pertuzumab in patients with HER2-positive early breast cancer (HELEN-006): a multicentre, randomised, phase 3 trial.
    Chen XC; Jiao DC; Qiao JH; Wang CZ; Sun XF; Lu ZD; Li LF; Zhang CJ; Yan M; Wei Y; Chen B; Feng YQ; Deng M; Ma MD; Plichta JK; He YW; Liu ZZ
    Lancet Oncol; 2024 Nov; ():. PubMed ID: 39612919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 study.
    Léna H; Greillier L; Cropet C; Bylicki O; Monnet I; Audigier-Valette C; Falchero L; Vergnenègre A; Demontrond P; Geier M; Guisier F; Hominal S; Locher C; Corre R; Chouaid C; Ricordel C;
    Lancet Respir Med; 2024 Oct; ():. PubMed ID: 39486424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decitabine, venetoclax, and ponatinib for advanced phase chronic myeloid leukaemia and Philadelphia chromosome-positive acute myeloid leukaemia: a single-arm, single-centre phase 2 trial.
    Short NJ; Nguyen D; Jabbour E; Senapati J; Zeng Z; Issa GC; Abbas H; Nasnas C; Qiao W; Huang X; Borthakur G; Chien K; Haddad FG; Pemmaraju N; Karrar OS; Nguyen D; Konopleva M; Kantarjian H; Ravandi F
    Lancet Haematol; 2024 Nov; 11(11):e839-e849. PubMed ID: 39303729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial.
    Askanase AD; D'Cruz D; Kalunian K; Merrill JT; Navarra SV; Cahuzac C; Cornelisse P; Murphy MJ; Strasser DS; Trokan L; Berkani O
    Lancet Rheumatol; 2024 Nov; ():. PubMed ID: 39586304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interventions for preventing weight gain after smoking cessation.
    Hartmann-Boyce J; Theodoulou A; Farley A; Hajek P; Lycett D; Jones LL; Kudlek L; Heath L; Hajizadeh A; Schenkels M; Aveyard P
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD006219. PubMed ID: 34611902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma.
    Yan Y; Tu Y; Cheng Q; Zhang J; Wang E; Deng Z; Yu Y; Wang L; Liu R; Chu L; Kang L; Liu J; Li X
    J Transl Med; 2024 Nov; 22(1):1087. PubMed ID: 39614361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.
    Pillay J; Gaudet LA; Saba S; Vandermeer B; Ashiq AR; Wingert A; Hartling L
    Syst Rev; 2024 Nov; 13(1):289. PubMed ID: 39593159
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted interferon therapy with modakafusp alfa for relapsed or refractory multiple myeloma.
    Vogl DT; Atrash S; Holstein SA; Nadeem O; Benson DM; Chaudhry M; Biran N; Suryanarayan K; Li C; Liu Y; Collins SC; Parot X; Kaufman JL
    Blood; 2024 Dec; ():. PubMed ID: 39630057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Sachdeva A; Jones C; Hoyle A; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Gilson C; Rush H; Abdel-Aty H; Amos CL; Murphy C; Chowdhury S; Malik Z; Russell JM; Parkar N; Pugh C; Diaz-Montana C; Pezaro C; Grant W; Saxby H; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzouebi M; Parikh O; Robinson A; Montazeri AH; Wylie J; Zarkar A; Cathomas R; Brown MD; Jain Y; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet Oncol; 2023 May; 24(5):443-456. PubMed ID: 37142371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.